NCT02561988
|
A Phase 1 Study of BLU-285 in Patients with Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies
|
Ryan Scannura, 720-848-8033
|
12
| NCT02567656 |
A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma |
Kelsey Moore, 720-848-8089 |
| NCT02443077 |
A randomized, double-blind, phase 3 study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with replapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype |
Tricia Feddick, 720-848-8034 |
| NCT02580552 |
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type |
Bradley Haverkos, 720-848-8698 |
| NCT02448381 |
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma |
Bradley Haverkos, 720-848-8698
|
| NCT02568267 |
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Bradley Haverkos, 720-848-8698 |
| NCT02731742 |
A Phase 1/1b Trial of MK-1966 (mAb against IL-10) in Combination with SD-101 (TLR9 agonist) in Subjects With Advanced Malignancies |
Bradley Haverkos, 720-848-8698 |
| NCT02327078 |
A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat (IDO inhibitor) Administered in Combination With Nivolumab in Select Advanced Cancers (including DLBCL) |
Bradley Haverkos, 720-848-8698 |
| NCT02635672 |
An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 (CDK9 inhibitor) in Patients With Advanced Hematological Malignancies (including NHL and CMYC+ NHL) |
Bradley Haverkos, 720-848-8698 |
| NCT02702492 |
A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin Lymphoma |
Bradley Haverkos, 720-848-8698 |
| NCT02465060 |
Molecular Analysis for Therapy Choice (MATCH) |
Bradley Haverkos, 720-848-8698
|
| NCT01943851 |
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies. |
Kelsey Moore, 720-848-8089
|
| NCT02561273 |
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma. |
Megan
Gager, 720-848-3773 |
| NCT02745769 |
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents. An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers. |
Bradley Haverkos, 720-848-8698 |
13No current trials recruiting
1
| NCT02848248 |
A phase 1 study of SGN-CD123A in patients with relapsed or refractory acute myeloid leukemia (AML). |
Kayla Fischer, 720-848-0736
|
NCT03013998
|
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia. (The Beat AML Trial). Novel study that pairs patients with one of multiple clinical trials running in parallel, depending on the unique biological features of that particular patient. |
Rachel Freeby, 720-848-0736
|
| NCT02203773 |
A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy. |
Rachel Freeby, 720-848-0736 |
NCT02326584 |
COMING SOON: A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML. Vadastuximab talirine (SGN-CD33A) in combination with cytarabine and daunorubicin (7+3) induction chemotherapy in newly-diagnosed acute myeloid leukemia patients. |
Daniel Pollyea, 720-848-0414 |
| NCT02577406 |
A phase 2, multicenter, open-label, randomized study comparing the efficacy and safety of AG-221 versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation.
|
Rachel Freeby, 720-848-0736
|
NCT02472145 |
A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy |
Shirstine Rahkola, 720-848-1776
|
| NCT02670044 |
A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy |
Shirstine Rahkola, 720-848-1776 |
10ClinicalTrials.gov
Identifier |
Study Title |
Study Coordinator |
|---|
| NCT01886859 |
A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Nicole Adler, 720-848-0678 |
2No current trials recruiting3
| NCT02508870 |
A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes. |
Ryan Scannura, 720-848-8033 |
| NCT02706899 |
A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS) |
Megan McClain, 720-848-3773 |
4
| NCT02755597 |
A phase 3, multicenter, randomized, double blind, study of Bortezomib and Dexamethasone in combination with either Venetoclax or placebo in subjects with relapsed or refractory multiple myeloma who are sensitive or naïve to proteasome inhibitors
|
Megan McClain, 720-848-3773
|
| NCT02576977 |
A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183) |
Kelsey Moore, 720-848-8089 |
5 ClinicalTrials.Gov
Identifier |
Study Title |
Study Coordinator |
|---|
| NCT02257567 |
A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. |
Emily Denoncourt, 720-848-0566 |
6No current trials recruiting7
|
|
|
| NCT02492737 |
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation. |
Natalie Monson, 720-848-2199 |
| NCT02257567 |
A phase IB/II study evaluating the safety, tolerability and anti-tumor activity of polatuzumab vedotin (dcds4501a) in combination with rituximab (r) or obinutuzumab (g) and bendamustine (b) in relapsed or refractory follicular or diffuse large b-cell lymphoma. |
Emily Denoncourt, 720-848-0566 |
| NCT02567656 |
A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma |
Kelsey Moore, 720-848-8089 |
8 ClinicalTrials.Gov
Identifier |
Study Title |
Study Coordinator |
|---|
| NCT01841333 |
A Phase 2 Study of PF-04449913 for the Treatment of Acute Leukemia Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse |
Natalie Monson, 720-848-2199 |
| NCT01690520 |
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes. |
Hayden Smith, 720-848-8026 |
9
|
|